{"id":390563,"date":"2018-10-26T00:00:00","date_gmt":"2018-10-26T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/biosbi0004-2018-biopharma-biosimilars-current-treatment-immunology-us-eu-2018\/"},"modified":"2026-03-31T10:47:49","modified_gmt":"2026-03-31T10:47:49","slug":"biosbi0004-2018-biopharma-biosimilars-current-treatment-immunology-us-eu-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/biosbi0004-2018-biopharma-biosimilars-current-treatment-immunology-us-eu-2018\/","title":{"rendered":"Biosimilars | Current Treatment | Immunology | US\/EU | 2018"},"content":{"rendered":"<p>Immune biologics including <abbr title=\"tumor necrosis factor\">TNF<\/abbr>-alpha inhibitors are among the most commercially successful biopharmaceutical products and therefore offer a great opportunity for biosimilars developers. The pipeline of immune biosimilars includes several agents that reference AbbVie\u2019s lucrative biologic Humira (adalimumab), which are available in Europe in October 2018, and biosimilars referencing Roche\u2019s Rituxan\/MabThera, which have already launched in Europe and are set to launch in the United States in Q3 2019. As the immune biosimilars space becomes increasingly competitive, it is important that manufacturers\/marketers of biosimilars\u00a0and branded biologics understand which factors influence physicians\u2019 uptake. Decision Resources Group has conducted market research with rheumatologists and gastroenterologists in France, Germany, and the United States to gain insights on physicians\u2019 attitudes toward biosimilars, the drivers and barriers to biosimilar use, and the expectations for biosimilar adoption.<\/p>\n<p><strong>Questions answered: <\/strong><\/p>\n<ul>\n<li>Have physicians received recommendations to use biosimilars?<\/li>\n<li>Are physicians switching patients from reference brands to biosimilars?<\/li>\n<li>What factors do physicians consider when choosing among competing biosimilars?<\/li>\n<li>How are <abbr title=\"tumor necrosis factor\">TNF<\/abbr>-alpha inhibitor and <abbr title=\"monoclonal antibody\">MAb<\/abbr> biosimilars performing, and what are physicians\u2019 expectations for their future uptake?<\/li>\n<li>What are the key drivers and barriers to the uptake of <abbr title=\"tumor necrosis factor\">TNF<\/abbr>-alpha inhibitors and <abbr title=\"monoclonal antibody\">MAb<\/abbr> biosimilars?<\/li>\n<\/ul>\n<p><strong>Scope: <\/strong><\/p>\n<ul>\n<li><!--[endif]--><strong>Markets covered<\/strong>: France, Germany, and the United States.<\/li>\n<li><strong>Primary research<\/strong>: Survey of 90 rheumatologists and 91 gastroenterologists.<\/li>\n<\/ul>\n<p><strong>Key companies mentioned:<\/strong><\/p>\n<ul>\n<li>Amgen.<\/li>\n<li>AbbVie.<\/li>\n<li>Biogen.<\/li>\n<li>Celltrion.<\/li>\n<li>Johnson &#038; Johnson\/Janssen.<\/li>\n<li>Merck &#038; Co.\/MSD.<\/li>\n<li>Mundipharma.<\/li>\n<li>Novartis\/Sandoz.<\/li>\n<li>Pfizer\/Hospira.<\/li>\n<li>Roche\/Genentech.<\/li>\n<li>Samsung Bioepis.<\/li>\n<\/ul>\n<p><strong>Key drugs mentioned:<\/strong><\/p>\n<ul>\n<li>Inflectra (infliximab).<\/li>\n<li>Remsima (infliximab).<\/li>\n<li>Benepali (etanercept).<\/li>\n<li>Flixabi (infliximab).<\/li>\n<li>Truxima (rituximab).<\/li>\n<li>Enbrel (etanercept).<\/li>\n<li>Humira (adalimumab).<\/li>\n<li>Remicade (infliximab).<\/li>\n<li>Rituxan\/MabThera (rituximab).<\/li>\n<li>Simponi (golimumab).<\/li>\n<li>Cimzia (certolizumab pegol).<\/li>\n<li>Orencia (abatacept).<\/li>\n<li>Actemra\/RoActemra (tocilizumab).<\/li>\n<li>Stelara (ustekinumab).<\/li>\n<li>Entyvio (vedolizumab).<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390563","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-biosimilars","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390563","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390563\/revisions"}],"predecessor-version":[{"id":576700,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390563\/revisions\/576700"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390563"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}